荣昌生物(09995.HK) 发盈警,预计2024年度净亏损约14.7亿人民币,较上年度减少4,100万人民币,减幅约3%。营业收入预计增加58%至17.15亿人民币。过往派息公布日期派息事项派息内容2024/10/29第三季业绩无派息2024/08/16中期业绩无派息2024/04/26第一季业绩无派息2024/03/27末期业绩无派息年内,公司新药研发管线持续推进,多个创新药处于关键试验研究...
Source Link荣昌生物(09995.HK) 发盈警,预计2024年度净亏损约14.7亿人民币,较上年度减少4,100万人民币,减幅约3%。营业收入预计增加58%至17.15亿人民币。过往派息公布日期派息事项派息内容2024/10/29第三季业绩无派息2024/08/16中期业绩无派息2024/04/26第一季业绩无派息2024/03/27末期业绩无派息年内,公司新药研发管线持续推进,多个创新药处于关键试验研究...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.